drugset
drugset / Trial / NCT00885963

A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

NCT00885963 ↗

Phase 2 Terminated 62 enrolled Cyclacel Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A phase II study to evaluate the safety and efficacy of oral sapacitabine in previously treated advanced non-small cell lung cancer (NSCLC).

Timeline

Start
2008-12-01
Primary completion
2013-08-13
Completion
2013-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject sapacitabine Small molecule — Oral

Indications

non-small cell lung carcinoma